Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. (29th July 2021)

• Record Type: Journal Article
• Authors: Giustozzi, Michela; Connors, Jean M.; Ruperez Blanco, Ana Belen; Szmit, Sebastian; Falvo, Nicolas; Cohen, Alexander T.; Huisman, Menno; Bauersachs, Rupert; Dentali, Francesco; Becattini, Cecilia; Agnelli, Giancarlo
• Is Part Of: Journal of thrombosis and haemostasis. Volume 19:Number 11(2021)
• Page Start: 2751
• Page End: 2759
• Publication Date: 2021-07-29
• Subjects: apixaban -- cancer -- incidental venous thromboembolism -- symptomatic venous thromboembolism -- venous thromboembolism; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15461
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Clinical guidelines advise similar anticoagulant treatment for symptomatic and incidental cancer‐associated venous thromboembolism (VTE). We investigated clinical features and outcomes of cancer patients with incidental or symptomatic VTE randomized in the Caravaggio study. Objectives: We performed a predefined sub‐analysis of the Caravaggio study in order to investigate the clinical features and outcomes of incidental and symptomatic VTE in patients with cancer. The relative efficacy and safety of apixaban and dalteparin in patients with incidental and symptomatic VTE was also assessed. Methods: The Caravaggio study compared apixaban to dalteparin for the 6‐month treatment of cancer‐associated VTE. The primary efficacy and safety outcomes were recurrent VTE and major bleeding. Results: Two hundred thirty patients (20%) had incidental and 925 (80%) symptomatic VTE. Pulmonary embolism with or without deep vein thrombosis as index event, colorectal cancer, Eastern Cooperative Oncology Group (ECOG) score of 0, and locally advanced or metastatic cancer were more frequent in patients with incidental VTE. Deep vein thrombosis as index event, hematological cancer, and ECOG score of 2 were more frequent in patients with symptomatic VTE. Ten patients (4.3%) with incidental and 68 (7.4%) with symptomatic VTE had recurrent VTE (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.29–1.10). Major bleeding occurred in 12 (5.2%) patients with incidental VTE and in 33 (3.6%) patients with symptomatic VTE (HR 1.43, 95% CI 0.74–2.77). When comparing apixaban to dalteparin in patients with symptomatic and incidental VTE, the HR for recurrence was 0.73 (95% CI 0.45–1.19) and 0.41 (95% CI 0.11–1.56), respectively, and the HR for major bleeding 0.93 (95% CI 0.47–1.83) and 0.96 (95% CI 0.31–2.96), respectively. Conclusions: Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding.